Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple myeloma, according to two oral abstracts presented at the American Society of Hematology meeting in San Diego over the weekend.